OBJECTIVES: The invasive growth of circulating tumor cells (CTCs) propagates cancer metastasis. The aims of this study were to evaluate the association of invasive CTCs, detected by a novel cell invasion assay, with disease stage, CA-125 level and patient survival. METHODS: Peripheral blood samples from 71 patients undergoing evaluation for ovarian malignancy were assessed for the presence of invasive CTCs using a cell invasion assay that enriches and identifies tumor cells with a cell adhesion matrix (CAM). Invasive CTCs were identified as cells exhibiting CAM invasion (CAM+) and expressing standard epithelial markers (Epi+). RESULTS: 43 (60.6%) patients had detectable CTCs: 0/5 benign patients, 1/10 (10%) early stage, 39/52 (73.1%) late stage and 3/4 (75%) unstaged patients (p-value <0.001). CTC counts ranged from 0-149 CTCs/ml with stage III/IV patients exhibiting significantly higher mean counts (41.3 CTCs/ml) than stage I/II patients (6.0 CTCs/ml) and benign patients (0 CTCs/ml, p-value=0.001). A positive correlation between CTC count and CA-125 level was observed (Spearman correlation coefficient r=0.309, p-value=0.035). Kaplan-Meier curves revealed a significant decrease in disease-free survival in patients with detectable CTCs (median survival 15.0 months vs. 35.0 months, log-rank p-value=0.042). Tumor grade and tumor histology did not influence CTC detection. CONCLUSIONS: Invasive CTCs can be detected in a majority of epithelial ovarian cancer patients and may predict shorter disease-free survival. Furthermore, higher CTC counts may reflect later stage disease and higher CA-125 levels.
OBJECTIVES: The invasive growth of circulating tumor cells (CTCs) propagates cancer metastasis. The aims of this study were to evaluate the association of invasive CTCs, detected by a novel cell invasion assay, with disease stage, CA-125 level and patient survival. METHODS: Peripheral blood samples from 71 patients undergoing evaluation for ovarian malignancy were assessed for the presence of invasive CTCs using a cell invasion assay that enriches and identifies tumor cells with a cell adhesion matrix (CAM). Invasive CTCs were identified as cells exhibiting CAM invasion (CAM+) and expressing standard epithelial markers (Epi+). RESULTS: 43 (60.6%) patients had detectable CTCs: 0/5 benign patients, 1/10 (10%) early stage, 39/52 (73.1%) late stage and 3/4 (75%) unstaged patients (p-value <0.001). CTC counts ranged from 0-149 CTCs/ml with stage III/IV patients exhibiting significantly higher mean counts (41.3 CTCs/ml) than stage I/II patients (6.0 CTCs/ml) and benign patients (0 CTCs/ml, p-value=0.001). A positive correlation between CTC count and CA-125 level was observed (Spearman correlation coefficient r=0.309, p-value=0.035). Kaplan-Meier curves revealed a significant decrease in disease-free survival in patients with detectable CTCs (median survival 15.0 months vs. 35.0 months, log-rank p-value=0.042). Tumor grade and tumor histology did not influence CTC detection. CONCLUSIONS: Invasive CTCs can be detected in a majority of epithelial ovarian cancerpatients and may predict shorter disease-free survival. Furthermore, higher CTC counts may reflect later stage disease and higher CA-125 levels.
Authors: A P M Heintz; F Odicino; P Maisonneuve; M A Quinn; J L Benedet; W T Creasman; H Y S Ngan; S Pecorelli; U Beller Journal: Int J Gynaecol Obstet Date: 2006-11 Impact factor: 3.561
Authors: T Fehm; S Becker; C Bachmann; V Beck; G Gebauer; M Banys; D Wallwiener; E F Solomayer Journal: Gynecol Oncol Date: 2006-08-04 Impact factor: 5.482
Authors: J M Cain; G K Ellis; C Collins; B E Greer; H K Tamimi; D C Figge; A M Gown; R B Livingston Journal: Gynecol Oncol Date: 1990-09 Impact factor: 5.482
Authors: Patricia L Judson; Melissa A Geller; Robin L Bliss; Matthew P Boente; Levi S Downs; Peter A Argenta; Linda F Carson Journal: Gynecol Oncol Date: 2003-11 Impact factor: 5.482
Authors: Janice Lu; Tina Fan; Qiang Zhao; Wei Zeng; Eva Zaslavsky; John J Chen; Michael A Frohman; Marc G Golightly; Stefan Madajewicz; Wen-Tien Chen Journal: Int J Cancer Date: 2010-02-01 Impact factor: 7.396
Authors: Katherine M Bell-McGuinn; Carolyn M Matthews; Steffan N Ho; Minal Barve; Lucy Gilbert; Richard T Penson; Ernst Lengyel; Rameshraja Palaparthy; Kye Gilder; Artemios Vassos; William McAuliffe; Sara Weymer; Jeremy Barton; Russell J Schilder Journal: Gynecol Oncol Date: 2011-01-26 Impact factor: 5.482
Authors: Scott M Langevin; E Andres Houseman; William P Accomando; Devin C Koestler; Brock C Christensen; Heather H Nelson; Margaret R Karagas; Carmen J Marsit; John K Wiencke; Karl T Kelsey Journal: Epigenetics Date: 2014-03-26 Impact factor: 4.528